NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study on Possible Interactions Between Protease Inhibitors (Anti-HIV Drugs) and Drugs Which Lower the Level of Fat in Your Blood

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 56

Registration Number: NCT00000941

Locations: 🇺🇸
Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
🇺🇸
San Francisco Gen Hosp, San Francisco, California, United States
🇺🇸
Stanford Univ Med Ctr, Stanford, California, United States

and more 10 locations

A Study of the Safety and Effectiveness of a Chickenpox Vaccine in HIV-Infected Children

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 127

Registration Number: NCT00000837

Locations: 🇺🇸
UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS, Los Angeles, California, United States
🇺🇸
SUNY Upstate Med. Univ., Dept. of Peds., Syracuse, New York, United States
🇺🇸
Usc La Nichd Crs, Los Angeles, California, United States

and more 22 locations

A Study to Evaluate the Effects of Giving IL-2 Alone to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3 Who Do Not Wish to Receive Anti-HIV Therapy

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 36

Registration Number: NCT00000909

Locations: 🇬🇧
Kobler Ctr. of Chelsea Westminster Hosp. C604-030 CRS, London, United Kingdom

Safety and Effectiveness of Giving Indinavir Plus Stavudine Plus Lamivudine to HIV-Infected Children

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-28

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 24

Registration Number: NCT00000901

Locations: 🇺🇸
UCSD Med Ctr / Pediatrics / Clinical Sciences, La Jolla, California, United States
🇺🇸
Univ of Florida Health Science Ctr / Pediatrics, Jacksonville, Florida, United States
🇺🇸
Incarnation Children's Ctr / Columbia Presbyterian Med Ctr, New York, New York, United States

and more 16 locations

A Phase I, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Thalidomide in Subjects With HIV-1 Infection

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-28

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 36

Registration Number: NCT00000812

Locations: 🇺🇸
University of Colorado Hospital CRS, Aurora, Colorado, United States
🇺🇸
University of Minnesota, ACTU, Minneapolis, Minnesota, United States
🇺🇸
Memorial Sloan-Kettering Cancer Ctr., New York, New York, United States

and more 3 locations

A Study to Test the Safety, Tolerance, and Metabolism of Abacavir (1592U89, ABC) With Standard Zidovudine (ZDV) Therapy in Newborn Infants Born to HIV-1 Infected Women

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-28

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 60

Registration Number: NCT00000864

Locations: 🇺🇸
Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States
🇺🇸
Bronx-Lebanon Hosp. IMPAACT CRS, Bronx, New York, United States
🇵🇷
San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico

and more 10 locations

Phase I Safety and Immunogenicity Trial of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (gp160; VaxSyn)

Phase 1

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-27

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 35

Registration Number: NCT00000630

Locations: 🇺🇸
UW - Seattle AVEG, Seattle, Washington, United States
🇺🇸
Vanderbilt Univ. Hosp. AVEG, Nashville, Tennessee, United States

ALVAC-HIV vCP1452 Alone and Combined With MN rgp120

Phase 2

Completed

Conditions: HIV Seronegativity
HIV Infections

Interventions: Biological: ALVAC(2)120(B,MN)GNP (vCP1452)
Biological: ALVAC(2)120(B,MN)GNP (vCP1452) placebo
Biological: MN rgp120/HIV-1 placebo
Biological: MN rgp120/HIV-1

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 160

Registration Number: NCT00011037

Locations: 🇵🇪
Barranco CRS, Lima, Peru
🇧🇷
Projeto Praça Onze/Hesfa Crs, Rio de Janeiro, Brazil
🇭🇹
Les Centres GHESKIO CRS, Port-au-Prince, Haiti

and more 1 locations

A Test of Behavioral Intervention for Women at High Risk for HIV Infection

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2016-10-31

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 180

Registration Number: NCT00006440

Locations: 🇺🇸
Anne Colletti, Cambridge, Massachusetts, United States

Pediatric Kidney Transplant Without Calcineurin Inhibitors

Not Applicable

Completed

Conditions: End-Stage Renal Disease

Interventions: Drug: Daclizumab
Drug: Methylprednisolone/prednisone
Drug: Mycophenolate mofetil
Drug: Sirolimus
Drug: Bactrim
Drug: Ganciclovir
Drug: Lipitor

First Posted Date: 2001-08-31

Last Posted Date: 2016-10-21

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 35

Registration Number: NCT00023231

Locations: 🇺🇸
Lauren Schenker, Rockville, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy